The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update

被引:3
作者
Rubboli, Andrea [1 ,2 ]
机构
[1] Osped Maggiore Bologna, Div Cardiol, I-40133 Bologna, Italy
[2] Osped Maggiore Bologna, Cardiac Catheterizat Lab, I-40133 Bologna, Italy
关键词
Oral anticoagulation; Warfarin; Antiplatelet agents; Percutaneous coronary intervention; Stent; HEART RHYTHM ASSOCIATION; ATRIAL-FIBRILLATION; ANTIPLATELET THERAPY; CONSENSUS DOCUMENT; EUROPEAN-SOCIETY; CLOPIDOGREL; WARFARIN; ASPIRIN; INTERVENTION; METAANALYSIS;
D O I
10.1007/s11739-011-0555-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Triple therapy (TT) of warfarin, aspirin, and clopidogrel is currently recommended as the optimal antithrombotic treatment in patients on long-term oral anticoagulation (OAC) for clinical conditions at moderate-high thromboembolic risk, such as moderate-high risk atrial fibrillation, mechanical heart valve, cardiogenic embolism, etc., who undergo coronary stent implantation. While being recognized as the most effective treatment for preventing major adverse cardiac events, stent thrombosis and stroke, TT is associated with an increased risk of bleeding, which apparently increases as the duration of TT is prolonged. Available evidence, however, is flawed by important limitations, including the limited size and retrospective design of most of the studies, as well as, the underreporting of the treatment that was actually ongoing at the time of an event. Recent data derived from larger, prospective studies have broadened and strengthened the recommendations that have been earlier issued by Scientific Associations. While confirming the overall superior net clinical benefit of TT in patients at moderate-high thromboembolic risk, recent data suggest that: (1) TT is likely associated with minor rather than major bleeding complications, and (2) accurate stratification of thromboembolic and bleeding risk may allow optimization of the antithrombotic treatment at discharge. Therefore, while still awaiting well designed, prospective, randomized trials, current data indicate that TT is the treatment of choice for patients on OAC at moderate-high thromboembolic risk, provided that meticulous review is frequently carried out in order to minimize and to detect early bleeding complications, while discontinuation of OAC and substitution with dual antiplatelet treatment is warranted in low-risk patients.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 26 条
  • [1] Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    Connolly, S.
    Pogue, J.
    Hart, R.
    Pfeffer, M.
    Hohnloser, S.
    Chrolavicius, S.
    Yusuf, S.
    [J]. LANCET, 2006, 367 (9526) : 1903 - 1912
  • [2] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [3] Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST)
    Dewilde, Willem
    Ten Berg, Jurrien
    [J]. AMERICAN HEART JOURNAL, 2009, 158 (05) : 713 - 718
  • [4] Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding
    Fauchier, Laurent
    Lip, Gregory Y. H.
    [J]. EUROPACE, 2010, 12 (06): : 761 - 763
  • [5] ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -: executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
    Fuster, Valentin
    Ryden, Lars E.
    Cannom, David S.
    Crijns, Harry J.
    Curtis, Anne B.
    Ellenbogen, Kenneth A.
    Halperin, Jonathan L.
    Le Heuzey, Jean-Yves
    Kay, G. Neal
    Lowe, James E.
    Olsson, S. Bertil
    Prystowsky, Eric N.
    Tamargo, Juan Luis
    Wann, Samuel
    Priori, Silvia G.
    Blanc, Jean-Jacques
    Budaj, Andrzej
    Camm, John
    Dean, Veronica
    Deckers, Jaap W.
    Despres, Catherine
    Dickstein, Kenneth
    Lekakis, John
    McGregor, Keith
    Metra, Marco
    Morais, Joao
    Osterspey, Ady
    Tamargo, Juan Luis
    Zamorano, Jose Luis
    Smith, Sidney C.
    Jacobs, Alice K.
    Adams, Cynthia D.
    Anderson, Jeffery L.
    Antman, Elliott M.
    Halperin, Jonathan L.
    Hunt, Sharon Ann
    Nishimura, Rick
    Ornato, Joseph P.
    Page, Richard L.
    Riegel, Barbara
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (16) : 1979 - 2030
  • [6] Comparison of Different Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation
    Gao, Fei
    Zhou, Yu Jie
    Wang, Zhi Jian
    Shen, Hua
    Liu, Xiao Li
    Nie, Bin
    Yan, Zhen Xian
    Yang, Shi Wei
    Jia, De An
    Yu, Miao
    [J]. CIRCULATION JOURNAL, 2010, 74 (04) : 701 - 708
  • [7] Antiplatelet Therapy in Patients With Anticoagulants Undergoing Percutaneous Coronary Stenting (from STENTIng and oral antiCOagulants [STENTICO])
    Gilard, Martine
    Blanchard, Didier
    Helft, Gerard
    Carrier, Didier
    Eltchaninoff, Helene
    Belle, Loic
    Finet, Gerard
    Le Breton, Herve
    Boschat, Jacques
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (03) : 338 - 342
  • [8] Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy
    Haelg, Christophe
    Brunner-La Rocca, Hans Peter
    Kaiser, Christoph
    Jeger, Raban
    Osswald, Stefan
    Pfisterer, Matthias
    Hoffmann, Andreas
    [J]. EUROINTERVENTION, 2009, 5 (04) : 425 - 431
  • [9] Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Hart, Robert G.
    Pearce, Lesly A.
    Aguilar, Maria I.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) : 857 - 867
  • [10] Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment
    Karjalainen, Pasi P.
    Vikman, Saila
    Niemela, Matti
    Porela, Pekka
    Ylitalo, Antti
    Vaittinen, Mari-Anne
    Puurunen, Marja
    Airaksinen, Tuukka J.
    Nyman, Kai
    Vahlberg, Tero
    Airaksinen, K. E. Juhani
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 (08) : 1001 - 1010